Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases
Authors' conclusion
Patients with ARD and lung cancer had better OS compared with their counterparts, independent of cancer stage and treatments and were less likely to have advanced stage lung cancer at diagnosis.
Study context
- Population
- Patients with lung cancer treated at Johns Hopkins
- Participants
- 10,963 patients
- Exposure
- Lung cancer patients with vs without autoimmune rheumatic diseases
- Autoimmune rheumatic diseases (ARD)n = 454
- Outcome
- Tumour characteristics at diagnosis and clinical (survival) outcomes
Methodological detailssingle-centre, logistic regression, Kaplan-Meier and Cox proportional hazards models
- Single-centre
- Logistic regression
- Kaplan-Meier and Cox proportional hazards models
Main finding
As reported in the abstract
Median overall survival (OS)
P < 0.001
Observational data: associations, not effects.
Further findings
Stage 1 lung cancer at diagnosis
P < 0.001
Mean
| Outcome | ARD | Without ARD | OR | P value |
|---|---|---|---|---|
| Smaller tumour sizeControlling for sex, race and histology | 0.76 | P = 0.01 | ||
| Age at diagnosis | 69 (SD 10) | 68 (SD 12) | P = 0.02 |
Factors associated with history of ARD
- Female sex, OR
- 1.75
- Smoking history, OR
- 1.46
- p<0.05
Original publication
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases. RMD Open. Published 31 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →